Phathom Pharmaceuticals, Inc. (PHAT) - Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company focused on gastrointestinal diseases, primarily commercializing VOQUEZNA (vonoprazan) for the treatment of erosive gastroesophageal reflux disease (Erosive GERD), non-erosive GERD, and H. pylori infection. The company operates as a single reportable segment.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Product Revenue, Net | $74.3 million | $132.6 million | $68.0 million |
| Gross Profit | $59.2 million | $105.5 million | $59.3 million |
| Gross Margin | 79.7% | 79.6% | 87.1% |
| Net Loss | $(17.6) million | $(48.0) million | $(170.1) million |
| Net Loss Per Share (Basic/Diluted) | $(0.21) | $(0.58) | $(2.36) |
| Cash and Cash Equivalents | $182.5 million (as of June 30, 2026) | ||
| Total Debt (Net of Discount) | $164.6 million (Long-term) + $37.3 million (Current portion of revenue interest financing) | ||
| Revenue Interest Financing Liability | $384.9 million (Total carrying value) |
Material Changes vs. Prior Period
- Revenue Growth: Net product revenue increased by 88.6% year-over-year for the six months ended June 30, 2026, driven by continued commercial execution and prescription volume growth for VOQUEZNA products.
- Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased by $70.4 million (39.2%) compared to the prior year period, primarily due to a $60.0 million reduction in advertising and promotional expenses following a restructuring plan implemented in May 2025.
- Improved Loss Profile: The net loss for the six months ended June 30, 2026, improved significantly to $(48.0) million from $(170.1) million in the same period in 2025.
- Debt Restructuring: In February 2026, the company entered into a Fifth Amendment to its Loan Agreement with Hercules Capital, securing a new $175 million term loan to repay existing obligations, extending the maturity date to February 2029, and eliminating payment-in-kind (PIK) interest.
- Capital Raise: In January 2026, the company completed an underwritten public offering, raising net proceeds of approximately $122.0 million.
Guidance, Outlook, and Risks
- Liquidity: Management believes existing cash ($182.5 million) and anticipated product revenues are sufficient to fund operations for at least the next twelve months.
- Commercial Outlook: The company continues to focus on U.S. commercialization of VOQUEZNA. As of July 17, 2026, approximately 1.7 million prescriptions have been filled since launch. The company has access for over 80% of U.S. commercial lives.
- Development Pipeline: Enrollment for a Phase 2 clinical trial evaluating vonoprazan for eosinophilic esophagitis (EoE) was completed ahead of schedule in June 2026. Topline results are expected in Q4 2026.
- Key Risks:
- Debt Covenants: The company must maintain specific minimum cash balances and performance metrics (revenue or market cap) under its Hercules Loan Agreement and Revenue Interest Financing Agreement.
- Supply Chain: Potential disruption in the supply of clarithromycin tablets (a component of VOQUEZNA TRIPLE PAK) remains a monitored risk, though no near-term disruption is currently anticipated.
- Revenue Interest Financing: The company is obligated to pay royalties to investors until they receive 200% of the investment amount ($260 million + additional funding), or make a cap payment. As of June 30, 2026, aggregate payments made were $28.9 million.
Investor Verification Checklist
- Verify the company's compliance with the minimum cash covenant (20% of outstanding principal) and performance covenant (revenue or market cap thresholds) under the amended Hercules Loan Agreement.
- Monitor the revenue interest financing liability accretion and the timing of royalty payments to investors, which impact interest expense and cash flow.
- Assess the impact of the clarithromycin supply chain on the availability of VOQUEZNA TRIPLE PAK, which represented ~1% of 2025 revenue but is a key H. pylori treatment option.
- Review the Phase 2 EoE trial results expected in Q4 2026 for potential new indications and revenue streams.
- Confirm the sustainability of the SG&A cost reductions achieved in 2025 and whether further cost-cutting measures are necessary to achieve long-term profitability.